Recombinant
RabMAb

Recombinant Anti-Telomerase reverse transcriptase antibody [Y182] - BSA and Azide free (ab181830)

Overview

  • Product name

    Anti-Telomerase reverse transcriptase antibody [Y182] - BSA and Azide free
    See all Telomerase reverse transcriptase primary antibodies
  • Description

    Rabbit monoclonal [Y182] to Telomerase reverse transcriptase - BSA and Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: IHC-Fr, WB, IPmore details
    Unsuitable for: ICC/IF
  • Species reactivity

    Reacts with: Cow, Human
  • Immunogen

    Synthetic peptide within Human Telomerase reverse transcriptase aa 1100-1200 (C terminal). The exact sequence is proprietary.

  • Positive control

    • IP: HeLa cells.
  • General notes

    Ab181830 is the carrier-free version of ab32020. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab181830 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Applications

Our Abpromise guarantee covers the use of ab181830 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration. PubMed: 17982423
WB Use at an assay dependent concentration. Detects a band of approximately 122 kDa (predicted molecular weight: 127 kDa).
IP Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for ICC/IF.
  • Target

    • Function

      Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.
    • Tissue specificity

      Expressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T lymphocytes, and at a low to undetectable level in peripheral blood T lymphocytes.
    • Involvement in disease

      Note=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.
      Defects in TERT are associated with susceptibilty to aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
      Note=Genetic variations in TERT are associated with coronary artery disease (CAD).
      Defects in TERT are a cause of dyskeratosis congenita autosomal dominant (ADDKC) [MIM:127550]; also known as dyskeratosis congenita Scoggins type. ADDKC is a rare, progressive bone marrow failure syndrome characterized by the triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.
      Defects in TERT are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF) [MIM:178500]. Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease.
    • Sequence similarities

      Belongs to the reverse transcriptase family. Telomerase subfamily.
      Contains 1 reverse transcriptase domain.
    • Domain

      The primer grip sequence in the RT domain is required for telomerase activity and for stable association with short telomeric primers.
      The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE) is required for interaction with the pseudoknot-template domain of each of TERC dimers. It contains anchor sites that bind primer nucleotides upstream of the RNA-DNA hybrid and is thus an essential determinant of repeat addition processivity.
      The RNA-interacting domain 2 (RD2) is essential for both interaction with the CR4-CR5 domain of TERC and for DNA sythesis.
    • Post-translational
      modifications

      Ubiquitinated, leading to proteasomal degradation.
      Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation by the AKT pathway promotes nuclear location.
    • Cellular localization

      Nucleus > nucleolus. Nucleus > nucleoplasm. Nucleus. Chromosome > telomere. Cytoplasm. Nucleus > PML body. Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.
    • Information by UniProt
    • Database links

    • Alternative names

      • CMM9 antibody
      • DKCA2 antibody
      • DKCB4 antibody
      • EST2 antibody
      • HEST2 antibody
      • htert antibody
      • hTRT antibody
      • PFBMFT1 antibody
      • TCS1 antibody
      • Telomerase associated protein 2 antibody
      • Telomerase catalytic subunit antibody
      • Telomerase reverse transcriptase antibody
      • Telomerase-associated protein 2 antibody
      • Telomere Reverse Transcriptase antibody
      • TERT antibody
      • TERT_HUMAN antibody
      • TP2 antibody
      • TRT antibody
      see all

    Images

    • ab32020 (purified) at 1:100 dilution (2µg) immunoprecipitating Telomerase reverse transcriptase in HeLa whole cell lysate.
      Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10µg
      Lane 2 (+): ab32020 & HeLa whole cell lysate
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab32020 in HeLa whole cell lysate
      For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1:1000 dilution.
      Blocking and diluting buffer: 5% NFDM/TBST.

    References

    This product has been referenced in:

    • Zaug AJ  et al. Many disease-associated variants of hTERT retain high telomerase enzymatic activity. Nucleic Acids Res N/A:N/A (2013). WB . Read more (PubMed: 23901009) »
    • Yang K  et al. p38? overexpression in gliomas and its role in proliferation and apoptosis. Sci Rep 3:2089 (2013). WB ; Human . Read more (PubMed: 23807566) »
    See all 15 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab181830.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up